Civi­ca nabs tri­al part­ner as it forges ahead to cre­ate more af­ford­able in­sulins

A non­prof­it drug man­u­fac­tur­er is mov­ing for­ward with plans to stem the ris­ing tide of in­sulin costs in the US.

Utah-based Civi­ca has se­lect­ed Ger­man-based re­search or­ga­ni­za­tion Pro­fil as its hu­man clin­i­cal tri­al part­ner to sup­port the de­vel­op­ment of Civi­ca’s af­ford­able in­sulins. Civi­ca is plan­ning to pro­duce three in­sulin biosim­i­lars – dubbed glargine, lispro and as­part – each of which will be avail­able both in vials and pre-filled pens.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN